Scarica l'app Stockscreener
73.07
0.94%
0.68
Dopo l'orario di chiusura:
73.13
0.06
+0.08%
Precedente Chiudi:
$72.39
Aprire:
$73.12
Volume 24 ore:
1.71M
Relative Volume:
0.71
Capitalizzazione di mercato:
$11.65B
Reddito:
$705.14M
Utile/perdita netta:
$-453.90M
Rapporto P/E:
-24.04
EPS:
-3.04
Flusso di cassa netto:
$-551.29M
1 W Prestazione:
+3.98%
1M Prestazione:
+19.17%
6M Prestazione:
+157.74%
1 anno Prestazione:
+86.59%
Intervallo 1D:
$72.07
$74.42
Intervallo di 1 settimana:
$69.40
$74.42
Portata 52W:
$23.95
$74.42
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
73.07 | 11.38B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Insider Sell Alert: B Parshall Sells 5,000 Shares of Ionis Pharm - GuruFocus
Ionis Pharmaceuticals EVP Birchler sells $1.72m in shares By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP research, Eric Swayze, sells $3901 in IONS stock - Investing.com Australia
Ionis Pharmaceuticals EVP Birchler sells $1.72m in shares - Investing.com
Ionis Pharmaceuticals director Parshall sells $358,721 in stock - Investing.com
Morgan Stanley Raises Price Target for Ionis Pharmaceuticals (IO - GuruFocus
Is Ionis Pharmaceuticals Inc. stock ready for breakoutWeekly Risk Summary & Precise Buy Zone Tips - newser.com
Morgan Stanley Raises Price Target on Ionis Pharmaceuticals to $90 From $86, Keeps Overweight Rating - MarketScreener
Ionis to hold third quarter 2025 financial results webcast - Business Wire
Lobbying Update: $140,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Ionis Pharmaceuticals stock hits 52-week high at 73.85 USD By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals stock hits 52-week high at 73.85 USD - Investing.com India
What recovery options are there for Ionis Pharmaceuticals Inc.July 2025 Drop Watch & Long-Term Safe Return Strategies - newser.com
Will Ionis Pharmaceuticals Inc. stock deliver better than expected guidanceIndex Update & Weekly Breakout Stock Alerts - newser.com
Sector ETF performance correlation with Ionis Pharmaceuticals Inc.July 2025 Trade Ideas & Entry Point Confirmation Signals - newser.com
Can Ionis Pharmaceuticals Inc. stock resist market sell offsJuly 2025 Trends & Low Risk Profit Maximizing Plans - newser.com
Published on: 2025-10-15 10:06:19 - newser.com
Why Ionis Pharmaceuticals Inc. stock remains on watchlistsJuly 2025 Snapshot & Daily Profit Focused Screening - newser.com
Can you recover from losses in Ionis Pharmaceuticals Inc.2025 Bull vs Bear & Safe Capital Growth Tips - newser.com
Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results - MSN
Earnings call transcript: Ionis Pharma’s Q2 2025 revenue doubles YoY - Investing.com
Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosPrice Action & Weekly High Return Forecasts - newser.com
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Growth, Innovation, and a Strategic Pipeline Fueling Investor Interest - DirectorsTalk Interviews
News impact scoring models applied to Ionis Pharmaceuticals Inc.Bull Run & AI Based Buy and Sell Signals - newser.com
Ionis Pharmaceuticals Hits New 52-Week High of $71.87 - Markets Mojo
A Look at Ionis Pharmaceuticals's Valuation Following Strong Phase 3 Data, New Approvals, and Analyst Upgrades - Sahm
Did Multiple FDA Approvals and Ambitious Guidance Just Shift Ionis Pharmaceuticals' (IONS) Investment Narrative? - Sahm
Can technical indicators confirm Ionis Pharmaceuticals Inc.’s reversalProduct Launch & Safe Entry Trade Signal Reports - newser.com
Will Ionis Pharmaceuticals Inc. price bounce be sustainableIndex Update & Fast Momentum Entry Tips - newser.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How Recent Milestones Are Shaping the Outlook and Valuation for Ionis Pharmaceuticals - Yahoo Finance
A Look at Ionis Pharmaceuticals's Valuation Following Pipeline Progress and Strong Innovation Day Updates - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $78.00 at Needham & Company LLC - MarketBeat
Eric Swayze Sells 6,849 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $937,375.34 in Stock - MarketBeat
Brett Monia Sells 437 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Poised To Break Even In 2028 Fueled By A Cadence Of Launches - insights.citeline.com
Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on pipeline strength - Investing.com Nigeria
Ionis Pharmaceuticals EVP Swayze sells $472k in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (NASDAQ:IONS) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Castle Rock Wealth Management LLC Invests $215,000 in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by DAVENPORT & Co LLC - MarketBeat
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP O’Neil sells $937k in IONS stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):